FeesSafety
Pluang+

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

16 Nov 2026, 22:00 WIB
Precedence Research
View Source
Bullish
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegovy, including new oral GLP-1 pills expanding access. Major competitors Pfizer, Roche, and Amgen are investing heavily in acquisitions and new drug development to challenge the leaders. The market growth is fueled by rising obesity rates, innovative therapies offering significant weight loss, and expanding manufacturing capacity, especially in North America and Asia Pacific. Oral formulations and longer-acting treatments are key trends shaping future competition.

Eli Lilly (LLY) trades at USD 1,467.62, significantly higher than Novo Nordisk (NVO) at USD 41.99 as of Nov 16, 2026 22:12 WIB, reflecting their different market capitalizations of $1.29T and $181.43B respectively. While NVO is closer to its 52-week low of $35.29 than its high of $63.98, Pfizer (PFE) at USD 29.21 is near its 52-week high of $30.79, showing varied investor sentiment among major players in the anti-obesity drug sector. Amgen (AMGN) trades near its 52-week high at USD 472.02, with a market cap of $251.89B, indicating strong positioning as it invests to challenge market leaders.

More News (LLY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App